After the third batch, a large number of pharmacies will close down, a batch of drugs will be cut....

"Pharmaceutical network market analysis" recently, the industry has been concerned about the third batch of collection results have been dust landing.
After the "great retreat" of foreign investment, the local "big melee", a total of 189 enterprises participated in this collection, resulting in 125 enterprises to be selected, 191 products to be selected, the average price of the products to be selected 53%, to a high decline of 95%.
also, according to Mienet data, the third batch of 56 varieties collected in 2019 in China's public medical institutions terminal total sales of more than 54 billion yuan.
the normalization of the collection of drugs has been opened, domestic generic drugs ushered in the era of micro-profits, will force pharmaceutical companies towards high-quality generic drugs, innovative drugs in the direction of transformation and upgrading.
in addition to pharmaceutical companies, the impact of the collection of drugstores, pharmaceutical representatives, pharmaceutical circulation and other industries.
a large number of retail pharmacies have 1000 retail pharmacies have been merged or eliminated in the third batch of collection, Guangdong Province has 28,000 pharmacies involved in the collection of the action has attracted the attention of the industry.
this participation is nearly half of the number of pharmacies in Guangdong Province, and in the participating pharmacies, the majority of pharmacies chains, single pharmacies accounted for less than 4%.
The industry generally believes that the pharmacy industry reshuffle has accelerated, according to past experience, for those drugstores that do not participate in the collection, it will be difficult to obtain the collection of varieties, will gradually lose the price competitive advantage, gradually lose customers, facing the situation of elimination.
In addition to facing the pressure of collection, with the outflow of prescriptions, hospitals will gradually give retail pharmacies to undertake the opportunity, drug sales main channels may be transferred from the hospital to professional pharmacies, Internet pharmaceutical e-commerce, in the process, the test is the level of pharmacy pharmaceutical services, leading enterprises or have a greater market share, pharmacy chaining will become a trend, a large number of retail pharmacies or be merged, or eliminated.
medical representatives or will usher in another wave of shuffle pharmaceutical representatives will also be affected by the collection policy.
whether it is the original research enterprises that abandon the bid directly, or the domestic pharmaceutical companies that have won the bid at low prices, the pharmaceutical representative industry will face greater pressure in the coming days.
, many pharmaceutical representatives said that regardless of their products will face layoffs, some pharmaceutical representatives said they will be transferred to the relevant market functions.
fact, medical representatives have not had a good time this year.
a joint inter-ministerial meeting held in August to correct the wrong wind in the field of pharmaceutical purchase and sale and medical services, it was highlighted that the anti-wind work in 2020 should continue to crack down on fraudulent fraud to defraud medical insurance funds, consolidate the effectiveness of the drug circulation sector, and resolutely clean up the industry chaos.
industry believes that this also means that in 2020 pharmaceutical representatives will usher in a major overhaul, the return to the academic standard has become an industry trend, the need to accelerate the transition from "relationship" and "transaction" to "technical".
can be seen, followed by medicine on behalf of the industry or will usher in a wave of shuffle.
Small and medium-sized pharmaceutical distribution enterprises will accelerate out of the other, from the Shanghai public list of collection and distribution enterprises, Beijing Jingfeng Pharmaceutical metformin and Hangzhou Kang enbe's non-nastamine tablets, respectively, by the national medicine, medicine package 96% of the drug distribution rights, the rest by Shanghai Kyushua and Shanghai Merro pharmaceutical distribution.
according to the reported amount, China National Pharmaceuticals, Shanghai Pharmaceuticals, Kyusju Tong and Merro will undertake about 70 million yuan, 120 million yuan, 2.36 million yuan and 5.7 million yuan of drug distribution tasks, respectively.
it is not difficult to see that the domestic drug circulation field is now tending to centralize development.
Industry believes that, with the four leading pharmaceutical circulation enterprises to accelerate the race, as well as in JD.com, Shunfeng, postal and other logistics giants under cross-border competition, small and medium-sized circulation enterprises will accelerate the process of exit in reverse.